id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-0776-0013,FDA,FDA-2021-D-0776,Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Guidance for Industry; Availability,Notice,Guidance,2022-11-07T05:00:00Z,2022,11,2022-11-07T05:00:00Z,,2022-11-07T13:31:59Z,2022-24112,0,0,0900006485492c29
FDA-2021-D-0776-0014,FDA,FDA-2021-D-0776,Studying Multiple Versions CGT Products Early Phase Clinical Trial Final 2022,Other,Guidance,2022-11-07T05:00:00Z,2022,11,2022-11-07T05:00:00Z,,2024-11-07T00:43:37Z,,1,0,0900006485493210
FDA-2021-D-0776-0001,FDA,FDA-2021-D-0776,"Studying Multiple Versions of a
Cellular or Gene Therapy Product in an
Early Phase Clinical Trial; Draft
Guidance for Industry; Availability",Notice,Notice of Availability,2021-09-30T04:00:00Z,2021,9,2021-09-30T04:00:00Z,2021-12-30T04:59:59Z,2021-12-24T02:00:16Z,2021-21322,0,0,0900006484db3b1a
FDA-2021-D-0776-0002,FDA,FDA-2021-D-0776,Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial Draft Guidance for Industry,Other,Guidance,2021-09-30T04:00:00Z,2021,9,2021-09-30T04:00:00Z,,2022-11-07T18:18:39Z,,0,0,0900006484db456e